Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC-Reference-Cited by-同舟云学术

Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC

Published:2023-10 Issue: Volume:573 Page:216366
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Wang Jianxin,Zhang Tengyi,Li Pan,Gai Jessica,Chen Sophia^ORCID,Espinoza Gigi,Kung Heng-Chung,Zhang Rui,Fujiwara Kenji^ORCID,Fu Juan,Yu Jun^ORCID,Zheng Lei^ORCID

Funder

Johns Hopkins University

Sidney Kimmel Comprehensive Cancer Center

Japan Society for the Promotion of Science

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference55 articles.

1. Pancreatic cancer;Mizrahi;Lancet (London, England),2020

2. Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers;Zhang;Cancer Lett.,2023

3. Therapeutic developments in pancreatic cancer: current and future perspectives;Neoptolemos;Nat. Rev. Gastroenterol. Hepatol.,2018

4. Activation of STING in the pancreatic tumor microenvironment: a novel therapeutic opportunity;Chamma;Cancer Lett.,2022

5. How the T cell receptor sees antigen--a structural view;Garcia;Cell,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration;Journal of Hematology & Oncology;2024-08-07

2. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application;Cancer Letters;2024-04

3. The recent advancement of TCR-T cell therapies for cancer treatment;Acta Biochimica et Biophysica Sinica;2024-03-01